# BIONOSTICS Quality Solutions

# K112356

510(k) Summary1

# SEP 19 2011

(a) (1) Submitter's name, address

Bionostics, Inc. 7 Jackson Road Devens, MA 01434

Contact Person Randy Byrd VP, Chief Technical Officer (978) 772-7070 x 272

Date of preparation of this summary: 15 August 2011

Device trade or proprietary name: Glucose Meter-Check Control for AgaMatrix Device common or usual name or classification name:

JJX Single (Specified) Analyte Control, All Types, Assayed and Unassayed

<table><tr><td>REGULATION MEDICAL SPECIALTY</td><td>-woond REGULATION NUMBER</td><td>1 ps M CLASS</td><td>REGULATION DESCRIPTION</td></tr><tr><td>Chemistry</td><td>862.1660</td><td>II</td><td>Glucose Control</td></tr></table>

I. Substantial Equivalence Glucose Meter-Check Control Solution for AgaMatrix substantially equivalent in function, safety and efficacy to currently marketed devices for the same intended use as shown in the following tables:

<table><tr><td>Characteristic</td><td>Predicate Device</td><td>Modified Device</td></tr><tr><td>Name:</td><td>WaveSense Control Solution</td><td>Glucose Meter-Check Control Solution for AgaMatrix</td></tr><tr><td>510(k), Date: Number of levels:</td><td>K052762, Jan 23 2006 2, typical fasting glucose and</td><td>1, typical fasting glucose</td></tr><tr><td>Target ranges: Analytes:</td><td>high, elevated blood glucose 111-169 and 298-448 mg/dl</td><td>105-158 mg/dL</td></tr><tr><td>Container: Fill volume:</td><td>glucose 6 mL LDPE vial with dispensing tip and cap</td><td>glucose 6 mL LDPE vial with dispensing tip and cap</td></tr></table>

# II. Description of the new device

Glucose Meter-Check Control Solution for AgaMatrix is a buffered aqueous solution with glucose containing no ingredients of biological origin, or in concentrations qualifying as a controlled product under the Controlled Products Regulation. The Glucose Meter-Check Control Solution is formulated for optimal performance on AgaMatrix glucose meters utilizing the WaveSense family of test strips.

# )  Intended use of the device

The Glucose Meter-Check Control Solution for AgaMatrix is intended for use to verify the performance and correct operation of the AgaMatrix blood glucose monitoring test systems utilizing the WaveSense family of blood glucose test strips. Glucose Meter-Check Control Solution for AgaMatrix is intended for use by healthcare professionals and people with diabetes mellitus at home.

) (Technological characteristics of the device.

This material consists of viscosity-adjusted, aqueous glucose control solution prepared with a single concentration of D-giucose with recovery on the test systems in the range typically considered normal, fasting glucose for a non-diabetic person. This solution has been optimized to simulate the response of whole blood on the blood glucose test systems manufactured by AgaMatrix and utilizing the WaveSense family of blood glucose test strips. The solution contains no hazardous, human or animal derived components.

Summary of non-clinical tests submitt with the premarket notification or the device.

Tests were conducted to verify specific performance requirements:

a) Closed bottle stability (Shelf-life) b) Stability after opening (Use-life) c) Transport Stability   
d) Test response

Sumay  clinical tsts ubmi wih he premarkt notiiation or the ice. N/A

(b) (3) Conclusions drawn from the clinical and non-clinical trials. Comparison of technological characteristics, formulation and intended use to predicate devices listed in this summary support the claim of substantial equivalence.

Bionostics, Ine. c/o Mr. Randy Byrd Chief Technical Officer 7 Jackson Road Devens, MA 01434

Re: k112356   
Trade Name: Glucose Meter-Check Control Solution for AgaMatrix   
Regulation Number: 21 CFR 862.1660   
Regulation Name: Quality control material   
Regulatory Class: Class I, reserved   
Product Codes: JIX   
Dated: August 15, 2011   
Received: August 16, 2011

Dear Mr. Byrd,

We have reviewed your Section S l0(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulieration.

If your device is classified (see above) into either class I1 (Special Controls) or class II1 (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR). Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809): medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manifacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2.

If you desie speciic advice for your device on our labeling regulation (21 CFR Par 801), piease conaci the Office of In Viro Diagnostic Device Evaluation and Safety al (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For quesons regarding postarke surveillance, please contaci CRH's Offic of Surveillance and Biometic's Dv  Sla  0Fo  rh adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manuacturers, International and Consumer Assistance a it toll-ree number (800) 638-204r (30179- 50orat isnterne address hp://www.da.goy/MedicalDevices/ResursforYou/ndustry/default.htm.

Sincerely yours,

![](images/b36b5de415d723a913bdb220f62f499f2136363f6e9a1daae49b189fe78837cb.jpg)

Courtney H. Lias, Ph.D.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

# Indications for Use

510(k) Number: K112356

Device Name: Glucose Meter-CheckÂ® Control Solution for AgaMatrix

Indications for Use: The.Glucose Meter-Check Control Solution for AgaMatrix is intended for use to verify the performance and correct operation of the AgaMatrix blood glucose monitoring test systems utilizing the WaveSense family of blood glucose test strips. Glucose Meter-Check Control Solution for AgaMatrix is intended for use by healthcare professionals and people with diabetes mellitus at home.

For In Vitro Diagnostic Use

Concurrent of CDRH, Office of Device Evaluation (OIVD)

![](images/fd7e5f039d8bb6a6ec48d9feb06e00808970b22fcad0b923bbe51469bc1287ae.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device Evaluation and Safety   
510(k) 1112356